Classification and treatment of vitreous seeds in retinoblastoma using intra-arterial and intravitreal techniques

Jasmine H Francis
Memorial Sloan Kettering Cancer Center, USA

Up until a decade ago, there was inadequate treatment for vitreous seeds in retinoblastoma and most of these eyes came to enucleation. However, with the increased use of both intra-arterial and intravitreal chemotherapy, the ocular survival rate for these eyes is now greater than 95%. As we salvage more of these eyes, our understanding of vitreous seeds has also improved greatly. Our group has previously proposed a classification system for vitreous seeds, which predicts response to and drug requirements for intravitreal melphalan. Furthermore, there are particular tumor, eye and patient characteristics that also correspond with the vitreous seeds classification. We, our recent advancements over the past decade and particularly the last two years, not only has our treatment of vitreous seeds in retinoblastoma greatly improved, but so has our understanding of this disease entity.

Biography
Jasmine H Francis is an attending Surgeon on the Ophthalmic Oncology Service at Memorial Sloan Kettering Cancer Center. She was voted one of the top 40 under 40 eye doctors by The Ophthalmologist.

francij1@mskcc.org

Notes: